Using a novel drug to target the STING pathway reprograms immune responses towards glioblastoma, providing a potential therapy for non-responsive patients.
Targeting the STING pathway activates the immune system against glioblastoma, which usually recruits immunosuppressive cells to support tumor growth.
[
add
]
[
|
|
...
]